In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fluvirin: PowderJect's Best Shot

Executive Summary

Expanding the market for flu vaccine Fluvirin is PowderJect's near-term priority, given that the product accounts for 65% of sales. But the drug-delivery-turned-vaccines player is also trying to realize value from its needle-free injection technology, by way of second-generation vaccines.

Related Content

PowderMed's Vaccines: Out of Chiron, Into the Clinic
PowderMed's Vaccines: Out of Chiron, Into the Clinic
Chiron/PowderJect: US Snaps Up Europe's Best
Shire Lays a Stake in Vaccines
Long End of the Stick
Feeling No Pain


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts